The Developmental Funds component of the CCSG is a critical resource for the UCLA Jonsson Comprehensive Cancer Center, as it provides the only continuing source of support from the CCSG to recruit new faculty and create new Program Areas and Shared Resources. The final authority over distribution of Developmental Funds resides with the Director, in consultation with the Director's Council. The highest priority is assigned to bringing new faculty recruits to UCLA and the JCCC through a search process in which the Cancer Center is a full partner. During the past funding cycle, Developmental Funds were used for recruitments to all 3 divisions of the JCCC (Basic/Translational, Clinical Translational and Prevention and Control). The return on these investments has yielded 195 cancer-related publications and ~$25M in cancerrelated funding. We plan to continue this focus for Developmental Funds in the future. The budgetary request for Developmental Funds in this renewal represents no increase over the current level. The JCCC Directorate considers recruitment and retention of faculty one of its most important duties. Other high-priority, developmental opportunities will be funded from philanthropic and institutional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-36
Application #
8208714
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
36
Fiscal Year
2011
Total Cost
$388,656
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Glenn, Beth A; Hamilton, Ann S; Nonzee, Narissa J et al. (2018) Obesity, physical activity, and dietary behaviors in an ethnically-diverse sample of cancer survivors with early onset disease. J Psychosoc Oncol 36:418-436
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714
Lisova, Ksenia; Sergeev, Maxim; Evans-Axelsson, Susan et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36-44
Chang, Yu-Ling; Rossetti, Maura; Vlamakis, Hera et al. (2018) A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol :
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146

Showing the most recent 10 out of 767 publications